Eli Lilly: Taltz plus Zepbound sustain improved psoriatic and metabolic outcomes at 52 weeks
- In TOGETHER-PsO, 30.6% of patients on Taltz plus Zepbound achieved PASI 100 plus ≥10% weight loss at Week 52 versus 4.4% with Taltz alone.
- In TOGETHER-PsA, 39.2% on the combination achieved ACR50 plus ≥10% weight loss at Week 52 versus 1.7% with monotherapy.
- PASI 100 was 40.5% at Week 52 with the combination versus 29.1% for Taltz alone, and ACR50 rose to 43.7% versus 15.7% with monotherapy.
- Systemic inflammation (hsCRP) and metabolic outcomes — BMI, blood pressure, glucose, HbA1c, triglycerides and total cholesterol — were sustained or further improved with the combination.
Study design and population
TOGETHER-PsO (n=274) and TOGETHER-PsA (n=271) are 52-week, randomized, multicenter, assessor-blinded, open-label Phase 3b studies comparing concomitant Taltz (ixekizumab) plus Zepbound (tirzepatide) versus Taltz alone in adults with moderate-to-severe plaque psoriasis or active psoriatic arthritis and obesity/overweight with at least one weight-related comorbidity. Participants were randomized 1:1, received counseling on reduced-calorie diet and increased physical activity, and had baseline mean BMIs of 39.2 (PsO) and 37.6 (PsA).
Efficacy at Week 52
Improvements seen at the Week 36 primary endpoint were maintained or further improved through Week 52. Primary composite outcomes: TOGETHER-PsO achieved PASI 100 plus ≥10% weight loss in 30.6% (combination) vs 4.4% (monotherapy); TOGETHER-PsA achieved ACR50 plus ≥10% weight loss in 39.2% vs 1.7%. Key secondary results included PASI 100 of 40.5% vs 29.1%, and ACR50 of 43.7% vs 15.7% with combination versus Taltz alone. hsCRP declined further and metabolic measures (BMI, blood pressure, glucose, HbA1c, triglycerides, total cholesterol) were sustained or improved. Week 52 analyses were pre-specified exploratory and descriptive without multiplicity control.
Safety and next steps
No new safety signals were identified; adverse events with the combination were generally mild to moderate and consistent with known profiles, with nausea, diarrhea, constipation, injection-site reactions, vomiting, dizziness and headache reported in ≥5% of the concomitant arm. Detailed 52-week results will be presented at medical meetings and submitted for peer-reviewed publication.
Source: Lilly
